Clinical Trial Update: CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast Cancer [Phase 2]

View source ↗

Summary

The CETRA Phase 2 trial of neoadjuvant Caelyx (pegylated liposomal doxorubicin) and trastuzumab in HER2-positive breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Caelyx (liposomal doxorubicin)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: National Cancer Institute, Naples | Conditions: Breast Cancer | Phase 2 | Status: WITHDRAWN